12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Fri, 03 Oct 2025 21:18:54 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Sat, 04 Oct 2025 21:18:54 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=PzPoEUD6x8Wwesv1M%2BBu%2ByzeY6djIxdc8rwwcKASMtgl7k2XjN6TSnXEFl3A2YNiK4UhgN9X9I1T2AcAo6vH7PHvxJCw9kkVndpqPn0%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Speculation-Rules: "/cdn-cgi/speculation" [21] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [22] => Server-Timing: cfEdge;dur=2,cfOrigin;dur=91 [23] => Set-Cookie: UpalLiveSession=eyJpdiI6IkZKcXc2RUEyRkZoaUF2NmxKbmFDY2c9PSIsInZhbHVlIjoiUnlIaFZEbHlhZnRzQmF5dFNtQ0Q5Z1lvWWttTENYQXkrd1pPMVBjTFBkVzFcL1wvcUtPUkdJcUxzRXgzM2RaeGVjeHlneXllYlAyejNkRXZ1N2JPdDdXUT09IiwibWFjIjoiMjE1YWNhYjZlOGU2OTc5MWZhZThmZmExYTRjYjY1ZTBkOTg5NTQ5OWI4ODNkODdmNTc0NTEzMmVhM2E4NTA3NSJ9; HttpOnly; Path=/; Max-Age=94608000; Expires=Mon, 02 Oct 2028 21:18:54 GMT [24] => CF-RAY: 988f7985cf279899-KUL [25] => alt-svc: h3=":443"; ma=86400 ) 789

 

 

联合药业（DPHARMA，7148，医疗保健组）公布，在截至2019年9月30日止第3财季录得强劲盈利，它将会继续进军特种产品领域，这是其创建利基产品的策略之一。

该集团在一份声明中说：“最近我们已获得注册批准，并推出一种名叫Erysaa的药品，它是红细胞生成素（EPO）。EPO是人体中存在的蛋白质，可根据人体对氧气的需求来调节红细胞的生长。”

所有贫血患者、肾透析急性贫血患者、因抗癌化疗而引起的贫血患者和需要输血的患者均可使用新配方的EPO作为治疗剂。

但是，联合药业指出，最近美元在全球范围内走强带来了挑战，因为它影响到生产和其他营运成本。

“预计将对制造部门利润率以及我们的利润构成压力。”

在截至2019年9月30日止第3财季，该集团的净利润按年从1228万令吉增加20.9％至1486万令吉，而收入则由之前的1亿2584万令吉上升13.5％至1亿4285万令吉。